Introduction {#Sec1}
============

Rheumatoid arthritis (RA) is a clinical diagnosis (or phenotype), considered to be the result of unidentified causes or insufficiently known pathophysiological malfunctions. Many conventional synthetic Disease-modifying anti-rheumatic drugs (csDMARDs) and biologicals (bDMARDs) are presently available and new treatment options and strategies have dramatically reduced the severity and impact of RA \[[@CR1]\]. Early intensive combination therapies, aimed at achieving remission, have shown especially good clinical outcomes \[[@CR2]--[@CR4]\].

Early diagnosis and treatment of RA may constrain the progression of this disease. Since there is no cure for RA yet, the most important goal is to achieve stable remission as soon as possible \[[@CR5]--[@CR7]\]. Despite considerable evidence from clinical trials on the efficacy and safety of treatment strategies aiming at inducing remission, also known as treat-to-target (T2T), a relevant proportion of RA patients in daily clinical practice still fail to become free of signs and symptoms \[[@CR8]--[@CR13]\].

In recent years, the T2T approach has also been studied in observational studies such as the DREAM remission induction registry \[[@CR3], [@CR14]\], showing that remission is also an achievable goal in clinical practice. Ideally, this is achieved by a highly successful treatment strategy that is suitable for all RA patients in daily clinical care. If not all patients can be treated successfully, we may need personalized approaches and identification of those individual characteristics pointing to specific successful treatments \[[@CR14], [@CR15]\]. This personalized medicine approach has resulted in the search of predictors in genetic and other biomarkers \[[@CR8], [@CR16]--[@CR18]\]. Unfortunately, until now major breakthroughs in predicting remission are lacking.

The DREAM remission induction cohort has demonstrated that T2T can be successfully implemented in a real life clinical setting. However, the question remains whether the T2T strategy fits all RA patients \[[@CR13]\]. Therefore, the aim of this study is to examine remission rates and predictors of remission in a real life cohort of consecutive patients with a recent diagnosis of RA.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

This study used data from the ongoing DREAM (Dutch Rheumatoid Arthritis Monitoring) remission induction cohort II, an observational, multicenter cohort that was established in 2012 to evaluate the effects of a T2T strategy of initial combination therapy of methotrexate (MTX) and hydroxychloroquine (HCQ) aimed at quickly achieving a state of remission (DAS28 \< 2.6) in early RA patients. Adults ≥ 18 years with a clinical diagnosis of RA and a disease duration \< 1 year were enrolled in our study. Consecutive patients from two hospitals in The Netherlands, Medisch Spectrum Twente in Enschede and Isala in Zwolle, were included as soon as they had been diagnosed with RA. The treatment strategy is in line with clinical practice and complies with the current guidelines for the treatment of RA. Exclusion criteria were the use of prednisolone ≥ 10 mg/day and/or previous or current treatment with DMARDs. The ethics committees of the participating hospitals determined, in accordance with the relevant law in the Netherlands, that no ethical approval was required because all data were collected in the course of regular daily clinical practice. Nonetheless, patients were fully informed and prior informed consent was obtained from each patient.

Treat-to-target protocol {#Sec4}
------------------------

Patients were evaluated at 0, 2, 4, and 6 months and every 3 months thereafter. Treatment advice consisted of an initial combination therapy of MTX 20 mg/week and HCQ 200 mg twice daily. As a bridging therapy, an optional intramuscular triamcinolone injection up to a maximum dosage of 120 mg could be given. After 1 month MTX dosage was increased to 25 mg/week, independent of disease activity. All patients who started MTX also received folic acid on the second day after MTX. After 2 months, in the case of persistent disease activity (DAS28 ≥ 2.6), MTX dosage was further increased to 30 mg/week and an extra optional intramuscular triamcinolone injection could be administered. After 4 months, in the case of moderate to high disease activity (DAS28 ≥ 3.2), a tumor necrosis factor (TNF) inhibitor (adalimumab, etanercept, or infliximab) was added. In cases of low disease activity (2.6 \< DAS28 \< 3.2), the attending rheumatologist could choose between adding sulphasalazine (SSZ) at 2000--3000 mg/day or an additional intramuscular triamcinolone injection.

Disease activity was assessed with the DAS28 during each subsequent visit. If remission (defined as DAS28 \< 2.6) had not been achieved, treatment was intensified. However, if the patient was in DAS28 remission, medication was not changed. In case of sustained remission (≥6 months), medication was progressively reduced and eventually discontinued according to a predetermined tapering schedule. In the case of disease flare (DAS28 ≥ 2.6), the most recent medication or medication dosage that was shown to be effective was restarted, and treatment could subsequently be intensified. In response to clinical indications, the attending rheumatologist was free to diverge from the medication schedule at any time.

### Measures {#Sec5}

At each assessment, data were collected on various core set measures, including measures of disease activity, health related quality of life, physical functioning, and laboratory measures. Disease activity was assessed by trained rheumatology nurses using the disease activity score for 28 joints (DAS28), consisting of 28 swollen and tender joint count, the erythrocyte sedimentation rate (ESR), and a 100 millimeter visual analog scale (VAS) on general health (where 0 = "very good" and 100 = "very bad") \[[@CR19]\]. The Health Assessment Questionnaire Disability Index (HAQ-DI) was used to assess physical function \[[@CR20]\]. Furthermore, patients rated their pain on a 100 millimeter VAS (0 = "no pain" and 100 = "unbearable pain") and completed the 36 items of the Short Form Health Survey (SF-36) in order to assess their current physical and mental health status \[[@CR21]\].

Statistical analysis {#Sec6}
--------------------

Missing values for ESR (total 5 %, baseline 0.7 %) and for CRP (total 0.8 %, baseline 0 %) were imputed based on age, sex, swollen and tender joint counts, and ESR, or CRP using single imputation by applying the expectation-maximization method. Descriptive statistics for normally distributed variables or categorical variables were reported as frequencies, percentages, means and standard deviations (mean ± SD). If variables were not normally distributed, the median with the corresponding interquartile range (IQR) was reported. Kaplan-Meier survival analysis was performed to examine DAS28 remission rates and to compute the time point at which 50 % of the patients had achieved their first DAS28 remission (DAS28 \< 2.6). Next, univariate logistic regression analyses were performed to examine associations between baseline variables and remission at the median survival time or within 1 year. Continuous predictors were evaluated for the suitability of the linearity assumption by plotting each variable against the logit of probability. Variables found to be related marginally (*p* \< 0.20) to DAS28 remission at 17 weeks or 52 weeks in the univariate analysis were entered into multivariable logistic regression analysis as independent variables. Results were expressed as odds ratios (ORs) with 95 % confidence intervals (CIs). The final model was tested for goodness of fit using the Hosmer and Lemeshow test. The explained variance of the model was examined using Nagelkerke's pseudo *R*^2^. All statistical calculations were performed using version 22 of the SPSS statistical package for Windows.

Results {#Sec7}
=======

Baseline characteristics {#Sec8}
------------------------

Table [1](#Tab1){ref-type="table"} summarizes the baseline characteristics of the total patient group and stratified by patients achieving remission or not at 6 months. A total of 137 patients were included. Patients had active disease at baseline, as demonstrated by high DAS28 scores and pain scores. Patients were, on average, 59 years old and the majority was female. Characteristics were similar between those that did or did not achieve remission at 6 months.Table 1Baseline characteristicsCharacteristicScore range of measureTotal group (*n* = 137)Remission at 6 months (*n* = 86)No remission at 6 months (*n* = 51)Female sex, *n* (%)--82 (59.9)48 (55.8)17 (33.3)Age, mean ± SD years--58.9 ± 13.559.0 ± 12.858.9 ± 14.9DAS28--ESR, mean ± SD0--104.9 ± 1.24.7 ± 1.25.2 ± 1.2DAS28--CRP, mean ± SD0--104.5 ± 1.24.4 ± 1.24.7 ± 1.2ESR (mm/h), median (IQR)0--14029.0 (15.0--46.0) (*n* = 136)24.5 (12.8--38.8)35.0 (18.0--53.0) (*n* = 50)CRP (mg/l), median (IQR)0--99912.0 (4.0--26.5)11.5 (4.0--27.0)13.0 (5.0--26.0)Anti-CCP positive, *n* (%)--83 (61.0) (*n* = 136)54 (62.8)29 (56.9) (*n* = 50)RF positive, *n* (%)--80 (58.4)48 (55.8)32 (62.7)Number of SJC, median (IQR)0--285.0 (2.0--10.0)5.5 (2.0--10.0)4.0 (2.0--10.0)Number of TJC, median (IQR)0--284.0 (2.0--11.0)3.5 (1.8--1.3)5.0 (2.0--11.0)HAQ-SDI, mean ± SD0--30.9 ± 0.7 (*n* = 90)0.9 ± 0.6 (*n* = 63)0.9 ± 0.8 (*n* = 27)VAS well-being, mean ± SD0--10051.9 ± 26.350.5 ± 25.254.3 ± 28.2VAS pain, mean ± SD0--10058.8 ± 22.3 (*n* = 75)60 ± 21.9 (*n* = 46)56.8 ± 23.1 (*n* = 29)SF36-PCS, mean ± SD0--10037.3 ± 9.2 (*n* = 88)37.6 ± 9.0 (*n* = 62)36.7 ± 9.9 (*n* = 26)SF36-MCS, mean ± SD0--10044.8 ± 11.9 (*n* = 88)44.9 ± 13.1 (*n* = 62)44.6 ± 8.3 (*n* = 26)BMI, kg/m^2^, mean ± SD--26.1 ± 4.0 (*n* = 128)26.1 ± 3.7 (*n* = 80)26.0 ± 4.4 (*n* = 48)*DAS28* disease activity score in 28 joints, *ESR* erythrocyte sedimentation rate, *CRP* C-reactive protein, *TJC* tender joint count, *SJC* swollen joint count, *HAQ-SDI* Health Assessment Questionnaire disability index (standard scoring), *SF-36* Short Form 36 health survey (version 2), *PCS* physical component summary, *MCS* mental component summary, *BMI* body mass index, *RF* rheumatoid factor, *Anti-CCP* anti-cyclic citrullinated peptide

Time to reach first remission {#Sec9}
-----------------------------

After 1 year of follow-up, remission (DAS28 \< 2.6) was achieved at least once in 77.2 % of the patients and the median time to first remission was 17.0 (95 % CI: 13.0--20.0) weeks (Fig. [1](#Fig1){ref-type="fig"}). A total of 71 patients (51.8 %) achieved remission within 17 weeks.Fig. 1Kaplan-Meier curve for time to reach first remission after a 1-year follow-up in early RA patients

Univariate associations with remission within 17 and 52 weeks {#Sec10}
-------------------------------------------------------------

Except for the baseline DAS28 score, none of the independent variables violated the assumption of linearity. Baseline DAS28 scores were dichotomized in high disease activity (\>5.1) versus low and moderate disease activity. None of the examined baseline variables were significantly associated with achieving remission within 1 year (Table [2](#Tab2){ref-type="table"}) and only lower HAQ-DI scores were marginally predictive of 1-year remission. Therefore, no multivariable model was tested for remission within 52 weeks. Lower ESR (*p* = 0.007), male gender (*p* = 0.057), and fewer tender joints (*p* = 0.175) were significantly or marginally associated with achieving remission within 17 weeks. As these variables were not strongly intercorrelated (all correlations \< 0.10), they were simultaneously entered into multivariable analysis.Table 2Univariate predictors of remission within 17 weeks and 52 weeksRemission within 17 weeksRemission within 52 weeksVariableOR95 % CIpOR95 % CI*p*High disease activity (DAS28 \> 5.1)0.5750.287--1.1510.1180.5960.266--1.3380.210BMI1.0230.937--1.1170.6140.9470.856--1.0480.292ESR0.9790.965--0.9940.0070.9920.977--1.0070.280CRP0.9960.985--1.0070.4601.0000.987--1.0120.940Anti-CCP positive0.7750.397--1.5140.4560.7610.348--1.6630.494RF1.1100.788--1.5640.5491.0710.710--1.6160.744Female sex0.5080.253--1.0190.0570.7750.338--1.7790.548Age0.9930.969--1.0180.5870.9880.959--1.0190.456HAQ-DI0.8200.444--1.5140.5260.6710.300--1.5000.331PCS1.0250.978--1.0740.3091.0140.954--1.0770.663MCS1.0090.973--1.0460.6211.0130.967--1.0620.577VAS general well-being0.9940.981--1.0070.3320.9930.977--1.0090.374SJC0.9780.922--1.0370.4541.0290.955--1.1080.452TJC0.9630.912--1.0170.1750.9690.912--1.0300.312*DAS28* disease activity score in 28 joints; *ESR* erythrocyte sedimentation rate; *CRP* C-reactive protein; *TJC* tender joint count; *SJC* swollen joint count; *HAQ-SDI* Health Assessment Questionnaire disability index (standard scoring); *SF-36* Short Form 36 health survey (version 2); *PCS* physical component summary; *MCS* mental component summary; *BMI* body mass index; *RF* rheumatoid factor; *Anti-CCP* anti-cyclic citrullinated peptide

Multivariate predictors of remission within 17 weeks {#Sec11}
----------------------------------------------------

The resultant multivariable model (Table [3](#Tab3){ref-type="table"}) showed an adequate fit to the data (Hosmer and Lemeshow test: χ^2^ (8) = 10.43 *p* = 0.24), but only lower baseline ESR remained significantly predictive (*p* = 0.005) of achieving remission within 17 weeks (Table [3](#Tab3){ref-type="table"}). No other variables were found to be significantly associated with remission and the total explained variance was low (13 %).Table 3Multivariate predictors of remission within 17 weeks in early RAPatients in remission in ≤ 17 weeksVariableOR95 % CIpESR0.9780.963 -- 0.9930.005Female sex0.5190.251 -- 1.0740.077TJC0.9590.905 -- 1.0170.163Nagelkerke *R* ^2^ = 0.129. *ESR* erythrocyte sedimentation rate; *TJC* tender joint count

Medication at 12 months {#Sec12}
-----------------------

At 12 months, 7.3 % (*n* = 10) of the patients were off medication entirely. The majority of the patients (54 %, *n* = 74) still used the initial combination medication of MTX + HCQ. In 9.5 % (*n* = 13) of the patients MTX monotherapy was used, while 13.9 % (*n* = 19) used another mono-csDMARD. MTX + bDMARD was used in 7.3 % (*n* = 10) of the patients at 12 months. Only one patient (0.7 %) was prescribed a bDMARD as mono therapy. The combination of two csDMARD and a bDMARD (MTX + HCQ + ADA) was used in 2.2 % of the patients (*n* = 3) and SSZ + HCQ was used in 1.5 % of the patients (*n* = 2). Five patients (3.6 %) were lost to follow-up (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Medication percentages of patients with early RA at 12 months

At baseline, 74 patients (54 %) received an intramuscular injection with triamcinolone. Furthermore, 30 patients (21.9 %) received triamcinolone injections between baseline and 12 months. Of these, 28 patients received one injection only 2 patients received 2 injections after baseline. Patients who received triamcinolone injections at baseline had significantly more swollen joints (8.0 (3.0--12.3) vs. 3.0 (2.0--6.0), *p* \< 0.001) and more tender joint (6.0 (2.0--12.0) vs. 4.0 (1.0--8.0), *p* = 0.039) than patients who did not receive a triamcinolone injection. There were no significant differences in general health and ESR between those that received a baseline triamcinolone injection and those that did not.

Discussion {#Sec13}
==========

This study demonstrated that almost 80 % of recently diagnosed RA patients rapidly achieved remission during the first year of their disease. Among a wide range of possible prognostic factors of achieving remission, no accurate predictors could be identified. This provides additional evidence that a T2T strategy aiming at remission is beneficial for recently diagnosed RA patients in clinical practice and should therefore be implemented widely.

The vast majority of the patients in the current study achieved the treatment target using csDMARDs only and only 10 % of patients needed to be prescribed a bDMARD within 12 months. In contrast to most previous T2T protocols, the protocol additionally allowed for optional intramuscular triamcinolone injections at the discretion of the treating rheumatologist. Interestingly, patients who received an injection at baseline generally had more swollen and tender joints than those who did not. However, there was no association with ESR or patient-reported general health. Apparently, the rheumatologists seemed to base their decision of using triamcinolone injections mostly on the number of affected joints and not on other indicators of disease activity. Future randomized studies could examine whether the number of affected joints is indeed a relevant indicator for the effectiveness of additional triamcinolone injections.

Fundamental, translational and clinical studies should ultimately lead to improvement of clinical care. Subsequent implementation in healthcare is often the real challenge; clinicians have to demonstrate that innovations are effective and safe, and contribute to increased health of the patient. The major strength of this study is the use of real life data from consecutive patients, recently diagnosed with RA, who were being treated according to a state of art T2T remission induction protocol. Limitations of the study are the relatively low number of patients (*n* = 137) and the absence of potential genetic predictors and other biomarkers. Also, in our study the follow-up period was only 1 year. Although this period of follow-up is not representative for the long patient journey of RA, until now successful early treatment is the best predictor of the future. However, longer follow-up is needed to establish whether current clinical remission rates prove sustainable \[[@CR22]\].

The current study examined the prognostic value of a wide range of commonly available demographic and disease-related variables. Among these, no predictors were identified for (not) reaching remission. While some markers appeared to be associated with early remission at 17 weeks, only ESR remained significantly predictive in multivariable analysis. The finding that low ESR at baseline was associated with achieving DAS28 remission at 17 weeks is not surprising, as ESR is one of the components of the DAS28. Moreover, this finding is in line with earlier studies by Forslind et al. \[[@CR23]\], who found that patients with high baseline DAS28 were less likely to achieve remission in all models and at all time points. Low ESR also showed a non-significant trend in the study by Vazquez et al. \[[@CR24]\] and Burmester et al. \[[@CR25]\] also found a univariate association with lower CRP, an acute phase reactant similar to ESR.

The finding that none of the potential predictors were significantly associated with achieving remission is in contrast with previous reports in early RA which have reported a variety of predictors ranging from sociodemographic characteristics, clinical and laboratory measures, to genetic markers. More specifically, female sex \[[@CR23], [@CR26], [@CR27]\], older age \[[@CR26], [@CR28]\], RF positivity \[[@CR17], [@CR23], [@CR29]\], and smoking \[[@CR30]\] were previously found to be associated with fewer non-remission periods. The finding that none of these factors were predictive in the present study may be due to the very high proportion of patients achieving remission (almost 80 %) in the current T2T strategy where other studies have reported remission percentages ranging from 10--65 % \[[@CR31]\].

In conclusion, the results of this study demonstrated that the current T2T strategy appears to be broadly applicable to all patients with recently diagnosed RA. Together with the absence of clear baseline predictors of remission, this suggests that clinicians in daily clinical practice may focus on DAS28 scores only, without needing to take other patients characteristics into account.
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